ACR 2020 Frequently Asked Questions

Sep 6th, 2020 - Please refer to the Frequently Asked Questions (FAQs) below for more information on the all-virtual ACR Convergence 2020. We will share more details as they become available in the coming weeks and months.

ACR 2020 Permissions and Reprints

Sep 6th, 2020 - ACR Convergence, the ACR's annual meeting, is a private event. Programs presented at the meeting are for the education of attendees and purchasers of recorded presentations as authorized by the American College of Rheumatology. The information and materials displayed and presented during this meeting are the property of the ACR and the presenter and cannot be photographed, copied, photocopied, ...

ACR 2020 General Meeting Information

ACR Convergence, the American College of Rheumatology’s 2020 annual meeting will be in Washington, D.C. November 6 - 11.

ACR/ARHP 2020 American College of Rheumatology Annual Meeting 2020

American College of Rheumatology Annual Meeting 2020 06-11 November 2020 Washington DC.

ACR 2020 Abstract Embargo Policies

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new ...

ACR 2020 Online Program

The Online Program is your source for educational content and program information for the 2020 ACR/ARP Annual Meeting. Look for topics of interest, bookmark sessions, and/or create a customized itinerary. Use the navigation menu to browse sessions, faculty, abstracts, and other meeting content. You can also use the advanced search tool to find sessions.

ACR 2020 Contacts

Registration and Hotels, Education, Abstracts, Exhibits, Press

ACR 2020 Abstracts

Submission, presentation, permission/reprints, embargo, ACR Convergence Awards

ACR 2020 Program

The program has hundreds of sessions to educate professionals in every segment of rheumatology.

ACR 2020 Image Competition Guidelines & Procedures PDF

The American College of Rheumatology (ACR) and the Association of Rheumatology Professionals(ARP) invite you to submit a case-based image and take advantage of the opportunity to have your work peer-reviewed by experts in the field. If accepted, your image will be digitally displayed in the distinguished international venue of ACR Convergence 2020 and be added to the ACR Rheumatology Image Libr...

ACR 2020 Image Competition

Call for Images, Submission Eligibility, Timeline, Permissions

Characterizing Morphea Subsets Using a Multi-center, Prospective, Cross-sectional Analysis
Jane Zhu, Smriti Prasad, Kaila Schollaert-Fitch et. al.

Nov 9th, 2020 - Background/Purpose: Morphea, or localized scleroderma, is an inflammatory condition of the skin and soft tissue that results in excessive collagen deposition, often producing permanent functional and cosmetic impairment. Morphea affects both adults and children, with approximately 50% of patients having childhood onset disease1,2. Numerous classification schemes for morphea exist, but none have...

Curdlan-induced Villous Permeability, Luminal Pathobiont Translocation to the Ileal Crypts, Ileitis and Arthritis Are Mitigated by Clostridia in Colonised Germ-free SKG Mice
Anne-Sophie Bergot, Rabina Giri, Amy Cameron et. al.

Nov 9th, 2020 - Background/Purpose: IL-23 dependent spondylitis, arthritis and inflammatory bowel disease (IBD) recapitulate human spondyloarthropathy (SpA) in 1,3 beta glucan (curdlan)-treated SKG mice. Human SpA and SKG mice have fecal dysbiosis, with increased Bacteroidaceae and Porphyromonadaceae. In SKG mice, anti-IL-23 supports homeostatic bacteria, including Clostridiaceae, which produce the short chain...

Clinically Important Improvements in Patients with Osteoarthritis Treated with Subcutaneous Tanezumab: Results from a 56-Week Randomized NSAID-Controlled Study
David Hunter, Tuhina Neogi, Melvin Churchill et. al.

Nov 9th, 2020 - Background/Purpose: Subcutaneous (SC) tanezumab, a monoclonal antibody that inhibits nerve growth factor, was investigated for the relief of signs and symptoms of moderate-severe OA in patients (pts) for whom use of other analgesics was ineffective or not appropriate in a randomized NSAID-controlled global long-term safety study (NCT02528188). The current analysis examines the effect of tanezum...

Comparison of Two Rituximab Regimens for Induction of Remission in Antineutrophil Cytoplasm Antibody-associated Vasculitis: Systematic Review and Meta-analysis
Valerie Benard, Cynthia Farhat, Melissa Zarandi-Nowroozi et. al.

Nov 9th, 2020 - Background/Purpose: Organ or life-threatening granulomatosis with polyangiitis (GPA) and microscopic polyangiitis (MPA), two of the antineutrophil cytoplasm antibody-associated vasculitis (AAV), are treated with cyclophosphamide or rituximab (RTX) in combination with glucocorticoids. Different RTX regimens for induction of remission are available: the 4-dose AAV regimen at doses of 375 mg/m2 I....

Circulating Biomolecules as Potential Biomarkers of Early and Establishedresponse to TNFi Therapy in Rheumatoid Arthritis Patients
Chary Lopez-Pedrera, Maria Luque-Tevar, Carlos Pérez-Sánchez et. al.

Nov 9th, 2020 - Background/Purpose: To evaluate changes produced in circulating inflammatory mediators and their regulatory miRNAs in RA patients after 3 and 6 months of treatment with TNF-α inhibitors (TNFi), in order to identify biomarkers of clinical efficacy and potential predictors of therapeutic response to TNFi therapies. Methods: In a prospective RA cohort multicenter study, serum from125 RA patients w...

Cutaneous Side Effects of Hydroxychloroquine in Rheumatic Diseases –Combination of “Traditional” Multivariate Analysis for Risk Factors AndClassification Model Development Using Supervised Machine ...
Sandeep Surendran, Mithun CB, Arun Tiwari et. al.

Nov 9th, 2020 - Background/Purpose: Hydroxychloroquine (HCQ) is associated with varied cutaneous side effects but only few studies in literature characterizing the risk factors for this. Recently machine learning tools have emerged as a promising option for predicting various outcomes. The aim of our study was to use “traditional” multivariate analysis along with novel machine learning (ML) methodology to anal...

Comparison of Work Productivity Outcomes Between Chronic Back Pain Patients with and Without a Diagnosis of Axial Spondyloarthritis After 2-Year Protocolised Follow-Up: Data from the Spondyloarthri...
Anne Boel, Miranda van Lunteren, Karen Fagerli et. al.

Nov 9th, 2020 - Background/Purpose: The aim of this study was to compare work-productivity and activity impairment outcomes after two-year follow-up between chronic back pain (CBP) patients with and without an axSpA diagnosis Methods: Patients over 16 years of age referred to the rheumatology outpatient clinic with chronic back pain (≥ 3 months < 2 years) starting before the age of 45, suspected of axSpA were ...

Comparative Effectiveness of Secukinumab, Adalimumab and Other Tumor Necrosis Factor Inhibitors in the Treatment of Axial Spondyloarthritis
Loïc Choquette Sauvageau, Denis Choquette, Louis Bessette et. al.

Nov 9th, 2020 - Background/Purpose: Studies comparing the effectiveness of biologics in the treatment of axial spondyloarthritis (axSpA) are sparse [1]. One study comparing secukinumab and adalimumab biosimilar is ongoing. Secukinumab is an agent targetting Il-17. The aim of our analysis is to compare the effectiveness of the most frequently used biologic in axSpA since the marketing of secukinumab in all, fir...